Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder

被引：21
作者：
Atuǧ F. [1 ]
Türkeri L. [1 ]
Özyürek M. [1 ]
Akdaş A. [1 ]
机构：
[1] Department of Urology, Ergun Özalp Research Laboratory, Marmara University, Istanbul
来源：
International Urology and Nephrology | 1998年 / 30卷 / 4期
关键词：
Bladder Cancer; Programme Cell Death; Bladder Tumour; Transitional Cell Carcinoma; International Urology;
D O I：
10.1007/BF02550226
中图分类号：
学科分类号：
摘要：
Bcl-2 and p53 genes are implicated in cell cycle regulation with roles on programmed cell death. Consequently, presence of Bcl-2 and nuclear accumulation of p53 were proposed to confer a growth advantage tumour cells. We have investigated their role as prognostic factors in fresh tumour samples from a cohort of twenty patients with transitional cell carcinoma of the bladder by immunohistochemical analysis in paired specimens. Expression of Bcl-2 was observed in 11 cases (69%) and nuclear p53 accumulation in 9 (45%). In the presence of Bcl-2 protein expression, tumours showed a slightly higher rate of recurrence (55% vs. 40%) and significantly more progression (36% vs. 0%). Recurrence and progression rates were not significantly different in tumours with and without nuclear p53 overexpression (recurrence rates 56% vs. 55% and progression rates 33% vs. 27%, respectively). Grade and stage appeared as important prognosticators since 75% of grade 3 tumours showed recurrence and 50% progressed in contrast to 44% and 13%, respectively, of grades 1 and 2 tumours. Similarly, 50% of Ta-T1 tumours recurred and 20% progressed, while these rates were 75% and 75% for T2-T3 tumours. Also, expression of Bcl-2 and nuclear accumulation of p53 correlated with grade. In grade 3 tumours, 75% showed nuclear p53 overexpression and 80% cytoplasmic Bcl-2 protein. These figures were 25% and 64% for grades 1 and 2 tmours. In conclusion, Bcl-2 protein expression in transitional cell carcinoma appears to be associated with a poorer prognosis and together with nuclear p53 overexpression they are associated with tumour de-differentiation.
引用
收藏
页码：455 / 461
页数：6
相关论文
共 20 条
  • [1] Özen, H., Bladder cancer (1996) Curr. Opin. Oncol., 8, p. 259
  • [2] Carson, D.A., Lois, A., Cancer progression and p53 (1995) Lancet, 346, p. 1009
  • [3] Lotem, J., Sachs, L., Regulation by bc1-2, c-myc and p53 susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation - Competent and defective myeloid leukemic cells (1993) Cell Growth Differ., 4, p. 41
  • [4] Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., Jacko, T., p53 is required for radiation-induced apoptosis in mouse thymocytes (1993) Nature, 362, p. 847
  • [5] Mercer, W.E., Shields, M.T., Lin, D., Apella, E., Ullrich, S.J., Growth suppression induced by wild-type p53 is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression (1991) Proc. Natl. Acad. Sci. USA, 88, p. 1958
  • [6] Fisher, D.E., Apoptosis in cancer therapy crossing the threshold (1994) Cell, 78, p. 539
  • [7] Miyashita, T., Krajewski, S., Krajewska, M., Wang, H.G., Lin, H.K., Liebermann, D.A., Tumor suppressor p53 is a regulator of bc1-2 and bax gene expression in vitro and in vivo (1994) Oncogene, 9, p. 1799
  • [8] Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C., Wahl, G.M., Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles (1993) Cell, 70, p. 937
  • [9] Hupp, T.R., Meek, D.W., Midgeley, C.A., Lane, D.P., Regulation of the specific DNA binding function of p53 (1992) Cell, 71, p. 875
  • [10] Levin, A.J., Momand, J., Finlay, C.A., The p53 tumour suppressor gene (1991) Nature, 351, p. 453
12